# A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

Study · id `cardio:ct-nct07285655` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07285655](<https://clinicaltrials.gov/study/NCT07285655>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07285655

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.

## Technical summary

Registry record NCT07285655. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-23 (actual); primary completion 2029-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 344 participants (planned count; ClinicalTrials.gov record NCT07285655, source copy `cardio:ctgov-nct07285655-2026-10-14`, retrieved 2026-10-31)
- Started: 2026-04-23 (actual) (ClinicalTrials.gov record NCT07285655, source copy `cardio:ctgov-nct07285655-2026-10-14`, retrieved 2026-10-31)
- Primary completion: 2029-07 (anticipated) (ClinicalTrials.gov record NCT07285655, source copy `cardio:ctgov-nct07285655-2026-10-14`, retrieved 2026-10-31)
- Completion: 2031-12 (anticipated) (ClinicalTrials.gov record NCT07285655, source copy `cardio:ctgov-nct07285655-2026-10-14`, retrieved 2026-10-31)
- Countries: United States; Australia; Austria; Belgium; Canada; France; Germany; Italy; Latvia; Portugal; Spain; United Kingdom (ClinicalTrials.gov record NCT07285655, source copy `cardio:ctgov-nct07285655-2026-10-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07285655-2026-10-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- Acronym: Re-Spire
- Condition: Pulmonary Hypertension Due to Lung Disease (Disorder)
- Intervention (Drug): L606
- Intervention (Drug): Placebo
- Lead sponsor: Liquidia Technologies, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)

## Provenance

Content hash: 114ab576d39aecdf79e5d050cf38c543c430da4e923ba12660977e0ca4e3133d
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
